Abstract: The invention provides a method for measuring the levels of 5-methyltetrahydrofolate (5-MTHF), tetrahydrofolate (THF), and 5,10-MTHF in a biological sample. The method includes employing an isotope dilution liquid chromatography-multiple reaction monitoring/mass spectrometry (LC-MRM/MS) methodology.

Abstract: The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the mRNA levels of a gene that responds to the drug, such as a steroid, to the mRNA levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid.

Abstract: The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the protein levels of a gene that responds to the drug, such as a steroid, to the protein levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid.

Abstract: A system and method may include monitoring communications between a user device, a website, and a behavioral tracking provider, capturing user information transmitted during the monitored communications, analyze the user information to determine one or more relationships between the user device, the websites, and the behavioral tracking provider, and outputting the one or more relationships to the user device.

Abstract: The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the protein levels of a gene that responds to the drug, such as a steroid, to the protein levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid.

Abstract: The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the mRNA levels of a gene that responds to the drug, such as a steroid, to the MRNA levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid.

Abstract: The present invention provides a system of injection molded panels having integrated connectors which combine to form a low profile enclosure having a telescoping roof. The panels are formed of injection molded plastic to interlock with one another without the need for separate I-beam connectors. The ends of the wall panels have cavities to accept both roof and floor outwardly projecting locking posts for interlocking cooperative engagement which serve to rigidly connect the components together. The construction of the wall, roof, floor and door components minimizes component shapes and simplifies enclosure construction.

Abstract: A plastic pipe cutting device for both cutting and filing a plastic pipe has a semi-circular top sleeve and bottom sleeve. A top guide track is connected to the top sleeve and a bottom guide track is connected to the bottom sleeve. The top guide track and the bottom guide track are continuous upon closing the device. A guide roller is rotatably connected to the roller housing and is capable of rolling upon the top and bottom guide track. A blade is connected to the roller housing for cutting a plastic pipe. A rasp is connected to the roller housing for filing the end of a plastic pipe.

Abstract: A biometric information management and enrollment system management system is provided. The system comprises a general purpose computer adapted for executing a computer software application; a card reader operatively connected to the computer for the transfer and storage of information to and from the computer; a digital camera operatively connected to the computer for the transfer of digital images to the computer; a fingerprint scanner operatively connected to the computer for the transfers of fingerprint information to the computer; wherein the software application adapted for controlling the computer, card reader digital camera, and fingerprint reader; wherein the software application having a graphical user interface having a task selection area and data display and manipulation area wherein the task selection determines the data display; and wherein the information comprise individual biometric information.

Abstract: The present invention provides a system of injection molded panels having integrated connectors which combine to form a low profile enclosure having a telescoping roof. The panels are formed of injection molded plastic to interlock with one another without the need for separate I-beam connectors. The ends of the wall panels have cavities to accept both roof and floor outwardly projecting locking posts for interlocking cooperative engagement which serve to rigidly connect the components together. The construction of the wall, roof, floor and door components minimizes component shapes and simplifies enclosure construction.

Abstract: The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the mRNA levels of a gene that responds to the drug, such as a steroid, to the mRNA levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid.

Abstract: The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the mRNA levels of a gene that responds to the drug, such as a steroid, to the mRNA levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid.

Abstract: The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the mRNA levels of a gene that responds to the drug, such as a steroid, to the mRNA levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid.

Abstract: The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the mRNA levels of a gene that responds to the drug, such as a steroid, to the mRNA levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid.

Abstract: The present invention is drawn to a method for the quantitative determination of human acute phase serum amyloid A protein (A-SAA) comprising contacting a sample of a biological fluid with antibody specific for A-SAA, the sample being reacted with an organic solvent prior to or simultaneous with antibody contact. The organic solvent is suitably a C1 or C4 alcohol and the antibody can be used on the solid phase and as a component of the detection system of an enzyme linked immunosorbant assay. The method provides a sensitive and reliable measure of A-SAA and inflammatory status which can be used for the diagnosis and clinical management of both acute and chronic inflammatory conditions.